Stroke Prophylaxis With Apixaban in Chronic Kidney Disease Stage 5 Patients With Atrial Fibrillation - SACK
The SACK trial aims to evaluate the safety and effectiveness of apixaban, an anticoagulant, for stroke prevention in patients with atrial fibrillation and advanced kidney disease (stage 5 CKD).
By comparing apixaban to no anticoagulation, the study seeks to determine whether it can reduce stroke risk without increasing the likelihood of major bleeding.
Sponsored by Karolinska Institutet, the, multicentre phase 3b trial have more than 35 sites across Sweden, Finland, Norway, Iceland, Poland, and the Netherlands. Patients with CKD stage 5 are randomized to standard of care without oral anticoagulation or with low dose apixaban 2.5 mg x 2. The study started in February 2022 and is planned to recruit 1000-1400 patients until December 2027. In Norway, six centers are participating, including our center in Tromsø.
The principal investigator is professor Marie Evans, Karolinska Institutet
The local P.I is Associate Professor Ludvig Balteskard Rinde
Members:
Financial/grant information:
Sponsored by Karolinska Institutet